SHALBY LIMITED is a Healthcare Services company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 699 | 805 | 934 | 1,087 | 1,141 |
| EBITDA (ex other income) | 115 | 137 | 177 | 133 | 143 |
| margin % | 16.5 | 17.0 | 19.0 | 12.2 | 12.5 |
| Owners' profit | 54 | 68 | 83 | 6 | 37 |
| EPS, as reported (₹) | 5.00 | 6.31 | 7.78 | 0.18 | 3.23 |
| ROE % · ROCE % | 6.2 · 8.3 | 7.3 · 10.2 | 8.3 · 11.2 | 0.2 · 7.6 | 3.4 · 7.9 |
| Debt / equity (x) | 0.20 | 0.19 | 0.31 | 0.43 | 0.54 |
| Cash from operations | 19 | 68 | 20 | (4) | (0) |
| Capex | (75) | (18) | (47) | (71) | (149) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 268 | 276 | 265 | 296 | 285 | 272 | 287 | 331 |
| Profit before tax | 14 | 12 | (1) | 23 | 19 | 9 | 10 | 20 |
| Net profit | 2 | (3) | (12) | 8 | 7 | 1 | 18 | 10 |
| EPS (₹) | 0.22 | (0.28) | (1.13) | 0.71 | 0.68 | 0.12 | 1.72 | 0.98 |
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Healthcare Services | 768 | 67.3 |
| Manufacturing of Implants | 68 | 6.0 |
| a) Healthcare Services | 242 | 21.2 |
| b) Manufacturing & Trading of Implants | 30 | 2.6 |
| Manufacturing & Trading of Implants | 33 | 2.9 |
| Total, before eliminations | 1,141 | 100.0 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · AGM 2026: 2 resolutions passed, director appointments rejected | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Shalby AGM: Financials passed, director appointment rejected by shareholders | board shareholder meetings | low | — | — |
| 10 Sept 2026 · Shalby 22nd AGM held via video conferencing, 4 resolutions transacted | board shareholder meetings | medium | — | — |
| 20 Aug 2026 · 22nd AGM on Sept 10, 2026; FY26 Annual Report weblink sent | compliance | minimal | — | — |
| 19 Aug 2026 · Shalby Q1 FY27 call: revenue up 12%, MedTech grows 53%, margin guidance raised | investor communications | medium | — | — |
| 19 Aug 2026 · Shalby publishes 22nd AGM notice and e-voting details in newspapers | compliance | minimal | — | — |
| 18 Aug 2026 · CEO of Shalby Medtech subsidiary resigns effective Sept 4 | management changes | high | — | — |
| 18 Aug 2026 · Shalby Medtech CEO Deepak Anand resigns effective Sept 4, 2026 | management changes | high | — | — |
| 17 Aug 2026 · Shalby files BRSR report for FY 2025-26 with exchanges | compliance | medium | — | — |
| 17 Aug 2026 · Shalby 22nd AGM notice on Sep 10, 2026; Annual Report FY 2025-26 sent | board shareholder meetings | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) |
| APOLLO HOSPITALS ENTER. L | 1,27,062 | 60.8 | 12.74 | 33.5 | 20.1 | 16.6 | 19.0 | 16.2 |
| MAX HEALTHCARE INS LTD | 1,00,993 | 69.2 | 9.40 | 44.0 | 13.4 | 11.1 | 27.3 | 27.0 |
| FORTIS HEALTHCARE LTD | 67,025 | 64.0 | 6.59 | 32.9 | 10.5 | 9.7 | 17.8 | 22.0 |
| ASTER DM QUALITY CARE LTD | 39,689 | 124.0 | 8.21 | 40.4 | 8.8 | 8.5 | (11.6) | 14.3 |
| GLOBAL HEALTH LIMITED | 38,972 | 70.0 | 9.78 | 39.4 | 13.9 | 13.5 | — | 23.7 |
| NARAYANA HRUDAYALAYA LTD. | 38,213 | 46.5 | 8.42 | 25.4 | 17.8 | 9.2 | 25.0 | 18.8 |
| KRISHNA INST OF MED SCI L | 32,235 | 150.5 | 12.60 | 43.4 | 9.5 | 5.1 | 24.0 | 20.3 |
| DR AGARWALS HEALTH CARE L | 16,043 | 107.9 | 7.57 | 26.2 | 7.9 | 7.1 | — | 28.8 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 41.4 | 47.3 | 14 of 30 | 55% |
| P/B | 1.6 | 6.2 | 3 of 24 | 91% |
| ROCE | 4.8 | 10.9 | 24 of 30 | 21% |
| ROE | 3.5 | 11.8 | 22 of 24 | 9% |
| Debt / Equity | 0.5 | 0.2 | 20 of 24 | 17% |
| EBITDA margin | 14.8 | 22.0 | 23 of 24 | 4% |
| Revenue growth | 11.7 | 20.2 | 19 of 23 | 18% |
| Profit growth | 36.7 | 8.1 | 7 of 21 | 70% |
| Market cap | 1557 | 2415 | 18 of 30 | 41% |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
